Charles River Labs (CRL) Tops Q2 EPS by 10c; Boosts FY11 Guidance
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $282.88 -0.52%
Financial Fact:
Cost of products sold: 69.33M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Cost of products sold: 69.33M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Charles River Laboratories International, Inc. (NYSE: CRL) reported Q2 EPS of $0.70, ex-items, $0.10 better than the analyst estimate of $0.60. Revenue for the quarter came in at $288.3 million versus the consensus estimate of $287.9 million.
Sees FY2011 EPS of $2.38-$2.48, versus prior guidance of $2.20-$2.40 and the consensus of $2.39.
Sees FY2011 EPS of $2.38-$2.48, versus prior guidance of $2.20-$2.40 and the consensus of $2.39.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Charles River Labs (CRL) PT Raised to $300 at TD Cowen
- MeiraGTx Holdings plc (MGTX) Tops Q2 EPS by 202c
- Forum Markets, Incorporated (FRMM) Tops Q2 EPS by 29c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
